Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Caris Life Sciences (CAI) Net Income towards Common Stockholders (2024 - 2025)

Caris Life Sciences has reported Net Income towards Common Stockholders over the past 2 years, most recently at $82.0 million for Q4 2025.

  • Quarterly results put Net Income towards Common Stockholders at $82.0 million for Q4 2025, up 232.3% from a year ago — trailing twelve months through Dec 2025 was -$472.9 million (changed N/A YoY), and the annual figure for FY2025 was -$538.0 million, down 42.22%.
  • Net Income towards Common Stockholders for Q4 2025 was $82.0 million at Caris Life Sciences, up from $24.3 million in the prior quarter.
  • Over the last five years, Net Income towards Common Stockholders for CAI hit a ceiling of $82.0 million in Q4 2025 and a floor of -$517.2 million in Q2 2025.